Designing a novel nano-vaccine against SARS-CoV-2

11Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

The new coronavirus SARS-CoV-2 has become a global pandemic, which has had a huge impact on the lives of people around the world and has caused huge impacts and losses on global economic development. To now, there is still no effective drug or therapy against coronavirus. A large number of studies have shown that vaccines are the ultimate weapon to eliminate major infectious diseases. The development of new vaccines against new coronaviruses is the best way to prevent new coronavirus infections. In this study, we developed a new vaccine against the new coronavirus by combining our self-developed nano adjuvant loaded with carnosine graphene oxide adjuvant with loaded with CpG molecule and RBD protein antigen. Our results showed that this vaccine can produce high titer anti-SARS-CoV-2 RBD antibody neutralizing SARS-CoV-2 in mice within 2 weeks.

Author supplied keywords

Cite

CITATION STYLE

APA

Gao, A., Liang, H., Shen, Q., Zhou, C., Chen, X. M., Tian, J., … Cui, D. (2020). Designing a novel nano-vaccine against SARS-CoV-2. Nano Biomedicine and Engineering, 12(4), 321–324. https://doi.org/10.5101/nbe.v12i4.p321-324

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free